Focused On-demand Library for Succinate dehydrogenase cytochrome b560 subunit, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q99643

UPID:

C560_HUMAN

Alternative names:

Integral membrane protein CII-3; QPs-1; Succinate dehydrogenase complex subunit C; Succinate-ubiquinone oxidoreductase cytochrome B large subunit

Alternative UPACC:

Q99643; O75609; Q3C259; Q3C2D8; Q3C2H4; Q5VTH3

Background:

The Succinate dehydrogenase cytochrome b560 subunit, mitochondrial, known alternatively as Integral membrane protein CII-3, QPs-1, Succinate dehydrogenase complex subunit C, and Succinate-ubiquinone oxidoreductase cytochrome B large subunit, plays a pivotal role in the mitochondrial electron transport chain. It is crucial for transferring electrons from succinate to ubiquinone, facilitating cellular energy production.

Therapeutic significance:

Linked to Paragangliomas 3 and Paraganglioma and gastric stromal sarcoma, this protein's genetic variants underscore its importance in disease pathogenesis. Understanding its role could lead to novel therapeutic strategies targeting these conditions, emphasizing the need for further research into its biological mechanisms and potential as a therapeutic target.